Article
Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
Cancer science - 1 Jun 2021
Ariyasu Ryo, Uchibori Ken, Sasaki Takaaki, Tsukahara Mika, Kiyotani Kazuma, Yoshida Ryohei, Ono Yusuke, Kitazono Satoru, Ninomiya Hironori, Ishikawa Yuichi, Mizukami Yusuke, Yanagitani Noriko, Fujita Naoya, Nishio Makoto, Katayama Ryohei
Abstract excerpt
Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is effective in treating both naïve and T790M-mutated EGFR-TKI-resistant non-small cell lung cancer patients. The EGFR C797S mutation is the major osimertinib resistance mechanism. The present study monitored the EGFR C797S mutation during osimertinib treatment in Japanese patients using droplet digital...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.